FDA Approves Mimrylo (rusfertide) for Polycythemia Vera
Key claim: On August 28, 2026 the FDA approved rusfertide (Mimrylo) for treatment of erythrocytosis in adults with polycythemia vera.
Abstract
The U.S. Food and Drug Administration approved Mimrylo™ (rusfertide), on August 28, 2026, for the treatment of erythrocytosis in adults with polycythemia vera (PV).
Why this matters
Rusfertide’s FDA approval is the first regulatory validation of a hepcidin-mimetic mechanism in any MPN subtype and is exclusive to polycythemia vera — reflecting PV’s unique iron-driven erythrocytosis biology that does not apply to ET, PMF, or CMML. It marks the first new PV-specific approval since ropeginterferon and converts the previously investigational hepcidin axis (also targeted by sapablursen and DISC-3405) into an approved therapeutic pillar alongside phlebotomy, hydroxyurea, ruxolitinib, and ropegIFN.